Related Experiment Video
Updated: Oct 3, 2025

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.3K
Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological
Senji Hoshi1, Vladimir Bilim2, Kiyotsugu Hoshi1
1Department of Urology Yamagata Tokushukai Hospital Yamagata Japan.
Clinical Case Reports
|February 14, 2022
Abstract:
Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration-resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra-physiological doses of testosterone.

